SEC Tracker
Get the app

Surrozen SRZN

Surrozen Q3 FY23: net loss $10.4M; diluted EPS −$0.34

Form
10-Q
Filed
Period
Importance
Notable
Document
10-Q
Exhibit 10.1
Material contract
Exhibit 10.2
Material contract

Key figures from this report

These are the numbers Surrozen reported for Q3 FY23, the quarter ended Sep 30, 2023, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Net income−$10.4MNo year-earlier figure tagged10-Q income statement, on EDGAR
  2. Diluted EPS−$0.34No year-earlier figure tagged10-Q income statement, on EDGAR
  3. Cash and cash equivalents$34.0MNo year-earlier figure taggedCash and equivalents only; the company page adds short-term investments.10-Q balance sheet, on EDGAR
  4. Cash from operations−$10.1MNo year-earlier figure tagged10-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when Surrozen files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.

  1. Sutro Biopharma STRO public float $60M, Jun 30, 2025
  2. PDS Biotechnology PDSB public float $60M, Jun 30, 2025
  3. iBio IBIO public float $58M, Dec 31, 2025
  4. Medicinova MNOV public float $62M, Jun 30, 2025
  5. Lifevantage LFVN public float $64M, Dec 31, 2025